Cingulate Inc. (CING) vs Champions Oncology, Inc. (CSBR)
A side-by-side comparison of Cingulate Inc. and Champions Oncology, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CING
Cingulate Inc.
$4.75HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
CSBR
Champions Oncology, Inc.
$4.97HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — CING vs CSBR
growth of $100 · dividends reinvested · last 5yCING -99.6% (-66.1%/yr)CSBR -40.2% (-9.8%/yr)CSBR compounded faster over this window
Log scale — wide-divergence pair
CING CSBR
CING vs CSBR: by the numbers
- •CSBR is the larger company ($69M vs $64M market cap).
- •Both run net losses; CING's is the smaller (0.00% vs -1.87% net margin).
Metrics side by side
Valuation
| Metric | CING | CSBR |
|---|---|---|
| Forward P/E | N/A | 49.70 |
| P/S ratio | N/A | 1.14 |
| P/B ratio | 2.73 | 17.74 |
| EV / EBITDA | 0.21 | 260.01 |
Profitability
| Metric | CING | CSBR |
|---|---|---|
| Gross margin | 0.00% | 49.30% |
| Operating margin | 0.00% | -1.72% |
| Net margin | 0.00% | -1.87% |
| ROE | -122.71% | -29.15% |
| ROIC | -83.74% | -6.75% |
Growth (annualized)
| Metric | CING | CSBR |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 7.25% |
| Total return CAGR (5Y) | N/A | -13.07% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.